Celcuity, Inc. (NASDAQ:CELC) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Celcuity logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Celcuity has a consensus “Moderate Buy” rating from 16 analysts: 13 rate it Buy, two Hold, and one Sell. The average 12-month price target is $151.79.
  • The stock opened at $53.36, near its one-year low of $53.20 and well below its one-year high of $151.02. Stifel lowered its target from $175 to $150 while maintaining a Buy rating.
  • Celcuity reported a quarterly loss of $1.21 per share, beating analysts’ expected loss of $1.51. It is a clinical-stage biotech developing targeted cancer therapies, including gedatolisib.
  • Interested in Celcuity? Here are five stocks we like better.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has been given an average rating of "Moderate Buy" by the sixteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $151.79.

CELC has been the subject of a number of recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Tuesday, September 1st. Stifel Nicolaus lowered their price objective on Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Citigroup reissued a "market outperform" rating on shares of Celcuity in a report on Monday, November 9th. Wall Street Zen raised Celcuity from a "strong sell" rating to a "sell" rating in a report on Saturday, November 14th. Finally, Citizens Jmp restated a "market outperform" rating and set a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th.

Get Our Latest Stock Analysis on CELC

Institutional Investors Weigh In On Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of CELC. PNC Financial Services Group Inc. grew its holdings in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company's stock worth $59,000 after acquiring an additional 86 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company's stock valued at $99,000 after purchasing an additional 124 shares during the period. Integrity Alliance LLC. lifted its stake in shares of Celcuity by 2.2% in the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company's stock valued at $944,000 after purchasing an additional 250 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Celcuity by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company's stock valued at $3,253,000 after purchasing an additional 297 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of Celcuity by 42.6% in the 3rd quarter. IFP Advisors Inc now owns 995 shares of the company's stock worth $79,000 after purchasing an additional 297 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

CELC opened at $53.36 on Friday. Celcuity has a one year low of $53.20 and a one year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 14.59. The company's 50 day simple moving average is $69.19 and its 200-day simple moving average is $96.86. The stock has a market capitalization of $2.62 billion, a P/E ratio of -11.33 and a beta of 0.16.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. Sell-side analysts anticipate that Celcuity will post -5.08 earnings per share for the current fiscal year.

Celcuity Company Profile

(Get Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Further Reading

Analyst Recommendations for Celcuity (NASDAQ:CELC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Celcuity Right Now?

Before you consider Celcuity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.

While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines